Patent 12233106

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

Original assignee

The original assignee on the issued patent is Biomarin Pharmaceutical Inc. Biomarin Pharmaceutical Inc. is a biotechnology company focused on developing and commercializing innovative therapies for people with serious and life-threatening rare diseases. It is an operating company that develops and ships products, including therapies for skeletal dysplasias. As of the current date, Biomarin Pharmaceutical Inc. is an active, operating company.

Assignment timeline

The USPTO Patent Assignment Search was performed for US Patent 12233106. No assignments were recorded for this patent after its issuance. The only recorded assignment is the initial assignment from the inventors to Biomarin Pharmaceutical Inc., which occurred before the patent's publication and issuance, as is standard practice. The "Current Assignee" section of the Google Patents page explicitly lists "Biomarin Pharmaceutical Inc".

Timeline diagram

timeline
    title Ownership of US 12233106
    2022 : Filed by Biomarin Pharmaceutical Inc
    2025 : Issued to Biomarin Pharmaceutical Inc

NPE / troll-pattern signals

  1. Shell-entity transfer — Not present. The patent remains with the original operating company, Biomarin Pharmaceutical Inc.
  2. Known asserter in the chain — Not present. There is no transfer to any known NPE.
  3. Repeat correspondent across the chain — Not present. There is only one recorded assignment (from inventors to the original assignee) and thus no chain of assignments to observe for repeat correspondents.
  4. Cascading transfers — Not present. There have been no post-issuance assignments.
  5. Pre-litigation transfer — Not present. There have been no post-issuance assignments.
  6. Bankruptcy fire-sale — Not present. Biomarin Pharmaceutical Inc. is an active operating company.
  7. Privateering — Not present. The patent remains with the original operating company.
  8. Defensive aggregator (anti-NPE) — Not present. The patent has not been acquired by a defensive aggregator.

Verdict

Insufficient data.
There are no recorded assignments for US12233106 after its issuance. The patent remains with the original operating company, Biomarin Pharmaceutical Inc., as shown by the Google Patents entry. Therefore, there is insufficient evidence to suggest any NPE / patent-troll patterns.

(Verification: https://assignmentcenter.uspto.gov/)

Generated 5/27/2026, 12:51:26 AM